Beta Bionics, Inc. (BBNX)

Market Cap	575.84M
Revenue (ttm)	88.57M +67.0%
Net Income	-77.84M
EPS	-2.50
Shares Out	44.02M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,293,513
Open	13.47
Previous Close	13.24
Day's Range	12.90 - 13.66
52-Week Range	8.89 - 32.71
Beta	n/a
Analysts	Strong Buy
Price Target	27.58 (+110.86%)
Earnings Date	Feb 17, 2026

About BBNX

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combine...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 2025
• Employees: 409
• Stock Exchange: NASDAQ
• Ticker Symbol: BBNX
• Website: https://www.betabionics.com

Financial Performance

In 2024, Beta Bionics's revenue was $65.12 million, an increase of 442.93% compared to the previous year's $12.00 million. Losses were -$54.76 million, 24.2% more than in 2023.

Analyst Summary

According to 12 analysts, the average rating for BBNX stock is "Strong Buy." The 12-month stock price target is $27.58, which is an increase of 110.86% from the latest price.

Price Target

$27.58

(110.86% upside)

Analyst Consensus: Strong Buy